Goodwin advised bit.bio on the agreement.BlueRock Therapeutics LP, a wholly owned, independently operated subsidiary of Bayer AG, and bit.bio announced a collaboration and option agreement for the…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
